<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123107</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0463</org_study_id>
    <nct_id>NCT03123107</nct_id>
  </id_info>
  <brief_title>Vitamin C in Cardiac Surgery Patients</brief_title>
  <official_title>Advancing the Cardiovascular Science of Vitamin C in Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wilkes University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery
      that increases the incidence of stroke, kidney injury and death. Vitamin C has been shown to
      decrease the incidence of POAF follow cardiac surgery, but the optimal dose has not been
      identified. With this project, the investigators plan to gather pharmacokinetic and
      dose-response data for vitamin C in the cardiac surgery population. The investigators plan to
      conduct a small interventional pilot study investigating the pharmacokinetics and
      pharmacodynamics of Vitamin C in patients undergoing coronary artery bypass graft (CABG)
      surgery. Patients enrolled will receive an intravenous dose of Vitamin C the day before
      surgery and the day after. Patients will have blood samples obtained with each dose for
      analysis of vitamin C concentrations and several biomarkers of oxidative stress. Analysis of
      samples will be performed within the Department of Pharmaceutical Sciences at Wilkes
      University.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiology of post-operative atrial fibrillation (POAF) in cardiac surgery patients
      has not been fully elucidated, but inflammation and oxidative stress are associated with its
      occurrence. Increased activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
      and production of glutathione and nitrotyrosine have been found to occur in animal models of
      atrial fibrillation and patients who develop POAF. Similarly, malondialdehyde (MDA), a
      biomarker of lipid peroxidation, has also been shown to increase during cardiac surgery, and
      be significantly more elevated in patients who develop POAF. Cardiac surgery patients
      supplemented with ascorbic acid have reduced expression of NADPH oxidase and levels of MDA,
      glutathione and nitrotyrosine, and reduced POAF rates. Ascorbic acid supplementation has
      demonstrated a significant reduction in POAF in small clinical trials enrolling patients
      undergoing cardiac surgery. Collectively, these findings show that ascorbic acid prevents
      POAF in a novel way compared to recommended therapies such as beta-blockers and amiodarone,
      without the risk of significant side effects. However, the doses of ascorbic acid utilized in
      clinical trials have been found to inadequately suppress the production of inflammatory
      markers associated with POAF. Therefore, the maximum effect of ascorbic acid for POAF
      prevention may not have been realized in clinical trials published to date. These suboptimal
      responses may be attributable to known variances in medication pharmacokinetics in the
      cardiac surgery population that lead to reduced medication bioavailability, metabolism and
      elimination. The variation in ascorbic acid pharmacokinetics in this population is unknown.
      Thus, the contribution of the proposed research is expected to be determination of the
      pharmacokinetic profile of ascorbic acid and its concentration-response relationship with
      oxidative biomarkers associated with POAF in the cardiac surgery population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ascorbate maximum serum concentration (Cmax)</measure>
    <time_frame>1 year</time_frame>
    <description>Maximum serum concentration of ascorbate obtained after drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of serum ascorbate (T1/2)</measure>
    <time_frame>1 year</time_frame>
    <description>The amount of time is takes for the serum concentration of ascorbate to decrease by half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant of ascorbate (Ke)</measure>
    <time_frame>1 year</time_frame>
    <description>The rate at which ascorbate is eliminated from the body</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve for serum ascorbate (AUC)</measure>
    <time_frame>1 year</time_frame>
    <description>Describes the overall concentration in the body given an administered dose of ascorbic acid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in biomarker concentrations</measure>
    <time_frame>Change within 24 hours; preoperative compared to postoperative</time_frame>
    <description>This will consist of the concentrations of NADP+, NADPH, MDA, GGS and nitrotyrosine in blood and atrial tissue samples.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Coronary Artery Bypass Graft Surgery</condition>
  <arm_group>
    <arm_group_label>Ascorbic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.</description>
    <arm_group_label>Ascorbic Acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 21 to 79 years of age admitted to Geisinger Wyoming Valley (GWV) and
             scheduled to undergo urgent CABG

          -  Planned utilization of cardiopulmonary bypass during the surgical procedure

        Exclusion Criteria:

          -  Body mass index greater than 30 kg/m2

          -  Estimated creatinine clearance less than 30 ml/min

          -  History of persistent or permanent atrial fibrillation

          -  Condition associated with oxidative stress or inflammation (e.g. chronic rheumatic,
             inflammatory or neoplastic disease, recent infection, etc.)

          -  Currently taking corticosteroids, non-steroidal anti-inflammatory drugs or
             deferoxamine

          -  History of oxalate kidney stones

          -  Currently pregnant

          -  History of allergic reaction to ascorbic acid products

          -  Currently taking any herbals or supplements (not including a multivitamin or calcium)

          -  Enrolled in another research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Bolesta, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Bolesta, PharmD</last_name>
    <phone>570-408-4203</phone>
    <email>sbolesta2@geisinger.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natacha M Antunes, MPH</last_name>
    <phone>570-714-6642</phone>
    <email>nmantunes@geisinger.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha Antunes, MPH</last_name>
      <phone>570-714-6642</phone>
      <email>nmantunes@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Scott Bolesta, PharmD</last_name>
      <phone>570-714-6643</phone>
      <email>sbolesta2@geisinger.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Bolesta, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deepak Singh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol. 2012 Jan 3;59(1):60-70. doi: 10.1016/j.jacc.2011.08.062.</citation>
    <PMID>22192670</PMID>
  </reference>
  <reference>
    <citation>Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997 Nov 18;96(10):3542-8.</citation>
    <PMID>9396453</PMID>
  </reference>
  <reference>
    <citation>Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001 Sep 14;89(6):E32-8.</citation>
    <PMID>11557745</PMID>
  </reference>
  <reference>
    <citation>Castillo R, Rodrigo R, Perez F, Cereceda M, Asenjo R, Zamorano J, Navarrete R, Villalabeitia E, Sanz J, Baeza C, Aguayo R. Antioxidant therapy reduces oxidative and inflammatory tissue damage in patients subjected to cardiac surgery with extracorporeal circulation. Basic Clin Pharmacol Toxicol. 2011 Apr;108(4):256-62. doi: 10.1111/j.1742-7843.2010.00651.x. Epub 2010 Dec 8.</citation>
    <PMID>21138533</PMID>
  </reference>
  <reference>
    <citation>Colby JA, Chen WT, Baker WL, Coleman CI, Reinhart K, Kluger J, White CM. Effect of ascorbic acid on inflammatory markers after cardiothoracic surgery. Am J Health Syst Pharm. 2011 Sep 1;68(17):1632-9. doi: 10.2146/ajhp100703.</citation>
    <PMID>21856809</PMID>
  </reference>
  <reference>
    <citation>Dehghani MR, Majidi N, Rahmani A, Asgari B, Rezaei Y. Effect of oral vitamin C on atrial fibrillation development after isolated coronary artery bypass grafting surgery: A prospective randomized clinical trial. Cardiol J. 2014;21(5):492-9. doi: 10.5603/CJ.a2013.0154. Epub 2013 Dec 2.</citation>
    <PMID>24293167</PMID>
  </reference>
  <reference>
    <citation>Dingchao H, Zhiduan Q, Liye H, Xiaodong F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg. 1994 Oct;42(5):276-8.</citation>
    <PMID>7863489</PMID>
  </reference>
  <reference>
    <citation>Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation. 2005 Aug 30;112(9):1266-73.</citation>
    <PMID>16129811</PMID>
  </reference>
  <reference>
    <citation>Eslami M, Badkoubeh RS, Mousavi M, Radmehr H, Salehi M, Tavakoli N, Avadi MR. Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. Tex Heart Inst J. 2007;34(3):268-74.</citation>
    <PMID>17948074</PMID>
  </reference>
  <reference>
    <citation>January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. Review. Erratum in: J Am Coll Cardiol. 2014 Dec 2;64(21):2305-7.</citation>
    <PMID>24685669</PMID>
  </reference>
  <reference>
    <citation>Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res. 2005 Sep 30;97(7):629-36. Epub 2005 Aug 25.</citation>
    <PMID>16123335</PMID>
  </reference>
  <reference>
    <citation>Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008 Jan 1;51(1):68-74. doi: 10.1016/j.jacc.2007.07.085.</citation>
    <PMID>18174039</PMID>
  </reference>
  <reference>
    <citation>Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001 Jul 10;104(2):174-80.</citation>
    <PMID>11447082</PMID>
  </reference>
  <reference>
    <citation>Papoulidis P, Ananiadou O, Chalvatzoulis E, Ampatzidou F, Koutsogiannidis C, Karaiskos T, Madesis A, Drossos G. The role of ascorbic acid in the prevention of atrial fibrillation after elective on-pump myocardial revascularization surgery: a single-center experience--a pilot study. Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):121-4. doi: 10.1510/icvts.2010.240473. Epub 2010 Nov 23.</citation>
    <PMID>21098510</PMID>
  </reference>
  <reference>
    <citation>Pea F, Pavan F, Furlanut M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet. 2008;47(7):449-62. Review.</citation>
    <PMID>18563954</PMID>
  </reference>
  <reference>
    <citation>Ramlawi B, Otu H, Mieno S, Boodhwani M, Sodha NR, Clements RT, Bianchi C, Sellke FW. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann Thorac Surg. 2007 Oct;84(4):1166-72; discussion 1172-3.</citation>
    <PMID>17888965</PMID>
  </reference>
  <reference>
    <citation>Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, Baeza C, Aguayo R, Castillo R, Carrasco R, Gormaz JG. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol. 2013 Oct 15;62(16):1457-65. doi: 10.1016/j.jacc.2013.07.014. Epub 2013 Jul 31.</citation>
    <PMID>23916928</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Geisinger Clinic</investigator_affiliation>
    <investigator_full_name>Scott Bolesta</investigator_full_name>
    <investigator_title>Visiting Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>Postoperative atrial fibrillation</keyword>
  <keyword>coronary artery bypass graft</keyword>
  <keyword>ascorbic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

